Dwayne Logan, MD
Ophthalmology · Long Beach, CANPI 1164520714
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 42.9% of the total. Reporting peaked in 2021 at $9,432 and has fallen 77.4% since, to $2,131 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $102.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$14K
- Ivantis, Inc$7K
- Alcon$4K
- Glaukos Corporation$3K
- AbbVie$834
- Bausch & Lomb Americas Inc.$415
- plus $3K from 18 others
Across 74 payments — averaging $2853.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$143K
- Aerie Pharmaceuticals, Inc.$29K
- Ocular Therapeutix, Inc.$26K
- Johnson & Johnson Surgical Vision, Inc.$7K
- Eyepoint US, Inc.$6K
What the payments were for
- Consulting fees$15,45048%
- Speaking & faculty fees$1,5005%
- Travel & lodging$1,6865%
- Food & beverage$13,79443%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 90 | $13,916 |
| Ivantis, Inc | 29 | $7,431 |
| Alcon | 63 | $4,294 |
| Glaukos Corporation | 24 | $2,776 |
| AbbVie(2 entities) | 35 | $834 |
| Bausch & Lomb Americas Inc. | 8 | $415 |
| Lumenis BE Inc | 1 | $414 |
| Amgen(2 entities) | 7 | $344 |
| Johnson & Johnson Vision Care, Inc. | 2 | $320 |
| Sight Sciences, Inc. | 9 | $264 |
| Rxsight Inc | 3 | $228 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $211 |
| Eyepoint US, Inc. | 1 | $166 |
| Oyster Point Pharma, Inc. | 5 | $156 |
| Sun Pharmaceutical Industries Inc. | 7 | $152 |
| Aerie Pharmaceuticals, Inc. | 6 | $97 |
| Ocular Therapeutix, Inc. | 5 | $84 |
| Novartis | 4 | $78 |
| Biotissue Holdings Inc. | 1 | $71 |
| Shire North American Group Inc | 3 | $66 |
| Staar Surgical Company | 1 | $40 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Thea Pharma Inc. | 1 | $23 |
| Welch Allyn | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$6,299
- Catalys Laser System$6,103
- COMPACT INTUITIV Phacofragmentation System$6,000
- Healon Viscoelastics$6,000
- Compact Intuitiv$3,450
- Healon Duet Pro$3,450
- STAR S4 IR$1,650
- LenSx$1,143
- Hydrus$898
- Tecnis IOL$741
- Tecnis Simplicity$585
- CATALYS SYSTEM$474
- M22$414
- KXL System$279
- MIEBO$266
- TEPEZZA$261
- iStent inject W$253
- ARGOS$221
- iDose$197
- AMO PHACO NEEDLE$187
How this compares
$32,430 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 80 | $82,065 |
| LumiganBimatoprost | 91 | $47,139 |
| Prednisolone Acetate | 1,221 | $38,095 |
| MoxifloxacinMoxifloxacin Hcl | 919 | $19,814 |
| Cyclosporine | 37 | $18,741 |
| RhopressaNetarsudil Mesylate | 48 | $17,423 |
| Brimonidine Tartrate | 332 | $15,441 |
| Ketorolac Tromethamine | 958 | $15,199 |
| Alphagan PBrimonidine Tartrate | 39 | $14,916 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $13,532 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 66 | $11,425 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $9,914 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 441 | $7,997 |
| Latanoprost | 601 | $6,864 |
| Methazolamide | 25 | $4,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $834 | $157,652251 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $97 | $27,33863 claims |
| AlconSimbrinza | $4,294 | $3,37513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Dan TranLong Beach$232K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.